Mitsubishi Chemical Industries Limited

Mitsubishi Chemical Corporation

Mitsubishi Kasei Corporation

Medichemie Ag

Hiroto Hara

Ryoji Kikumoto

Harukazu Fukami

Kunihiro Ninomiya

Hisao Takayanagi

Yasunori Kitano

Mamoru Sugano

Hiroe Umeki

Tamaki Yano

Yoshikuni Tamao

Hideo Nakamura

Akihiro Narimatsu

Koichi Sugawara

Kyoji Kikumoto

Masanori Osakabe

Toshiko Oshino

Haruki Inokawa

Benzoylethylene derivative

A pharmaceutical composition which comprises a pharmaceutically effective amount of a compound of the formula ##STR1## wherein R.sup.1 represents a hydrogen atom, R.sup.2 represents --(CH.sub.2).sub.m -A wherein m is an integer of 0 to 3, and A represents pyridyl which is unsubstituted or is substituted by C.sub.1 -C.sub.3 alkyl said alkyl being unsubstituted or substituted by phenyl, and R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 each independently represent a hydrogen atom, a halogen atom, C.sub.1 -C.sub.5 alkyl which is unsubstituted or is substituted with a halogen atom or --OR.sup.13 wherein R.sup.13 represents a hydrogen atom or C.sub.1 -C.sub.5 alkyl which is unsubstituted or is substituted with a halogen atom or phenyl, or when their adjacent substituents are taken together, they represent C.sub.1 -C.sub.3 oxyalkylene having one or two oxygen atoms; or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier therefor.

Tyrosine kinase inhibitors and benzoylacrylamide derivatives

Styrene derivatives of the following general formula (I): ##STR1## or pharmaceutically acceptable salts thereof. A pharmaceutical composition useful as anticancer agent, which comprises the above compound as an essential component, is also provided.

Styrene derivatives

A method of suppressing vasoconstriction in a warm-blooded animal which comprises administering to said warm-blooded animal an effective amount of a serotonin antagonist compound of the formula (I): ##STR1## wherein: R.sup.1 is hydrogen, halo, C.sub.1 -C.sub.5 alkoxy or C.sub.2 -C.sub.6 dialkyl amino;

Serotonin antagonist

(3-Aminopropoxy)bibenzyl derivatives are prepared and found useful as pharmaceutical agents, particularly as inhibitors of platelet aggregation.

Pharmaceutically active (3-cyclic aminopropoxy)bibenzyls as inhibitors

Pharmaceutically active (3-aminopropoxy)bibenzyl derivatives

Caroverine fumarate has an inhibitory effect on platelet aggregation, and exhibits the beneficial effect of increasing coronary blood flow, especially in coronary arteries, and thus is specifically suitable in applications for ischemic heart diseases.

Methods of inhibiting blood platelet aggregation with caroverine fumarate

(Omega-aminoalkoxy)bibenzyls are prepared and found useful as pharmaceutical agents, particularly as inhibitors of platelet aggregation.

Pharmaceutically active (omega-aminoalkoxy)bibenzyls

Growing community of inventors

Machida, Japan

Hiroto Hara